Skip to main content

Burgess and Gingrich: Protecting the Investment of a Kidney


08.11.20

Washington, D.C. –  Rep. Michael Burgess, M.D. (R-TX) along with former House Speaker Newt Gingrich penned an op-ed in RealClearHealth on why H.R. 5534, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act, should be passed in Congress and signed into law. This bill would cover immunosuppressive drugs under Medicare beyond the current 36-month coverage if a patient who has received a kidney transplant is unable to receive another type of coverage. The Energy and Commerce Health Subcommittee Republican Leader and former Speaker of the U.S. House of Representatives argue that this policy would help patients while also saving taxpayer dollars. H.R. 5534 was passed out of the Energy and Commerce Committee with unanimous support on July 15th.

RealClearHealth
Protecting the Investment of a Kidney
August 9, 2020
By Rep. Michael Burgess, M.D. (R-TX) and Newt Gingrich

A crucial component of any kidney transplant is the delivery and maintenance of a consistent immunosuppressive medication regimen. Without these medications, the patient will likely reject the gift of the transplanted organ and be forced to return to dialysis—a time-intensive and expensive treatment.

Because of the astronomical expense of treating end-stage renal disease (ESRD) with dialysis, in 1972, Congress made it possible for individuals living with ERSD to become eligible for Medicare, regardless of their age or disability status.

Patients with ESRD constitute roughly 7 percent of Medicare fee-for-service spending but only make up 1 percent of total enrollment for Medicare. These patients are incredibly ill and often have other costly chronic conditions. At the start of dialysis, 93 percent of patients between 18 and 54 years of age are classified as disabled, and more than 100,000 Americans begin dialysis each year due to kidney failure.

Under Medicare’s ESRD benefit program, patients like Wiley are eligible for coverage during their dialysis treatments and when the receive their transplant. However, their immunosuppressive medications are only covered for the first 36 months of their treatments. Kidney recipients require these drugs for the rest of their lives, or they risk their bodies rejecting the transplants. So, after they’ve gone through the harrowing experience and trauma of undergoing dialysis and an organ transplant, patients who can’t find other health insurance must then face down a life-long, crippling expense. If they can’t afford the immunosuppressive drugs, the patient’s body will reject the kidney and they are back on dialysis.

Further, from the taxpayer’s perspective, only covering these medications for 36 months is like throwing money down the drain—or in this case not just money but the precious gift of a kidney. If patients’ kidneys are rejected, Medicare pays for dialysis treatments again, costing taxpayers approximately $90,000 per patient every year. Immunosuppressant drug coverage costs Medicare an average of $2,303 per patient per year. Patients who can afford the drugs can go on to live active, productive lives. That means 45 patients could be treated with immunosuppressant drugs for one person getting dialysis. Yet the government pays for the vastly more expensive therapy and limits payment for the radically less expensive treatment. For both ethical and financial reasons, it is clear this policy must change.

The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019, H.R. 5534, directly addresses this problem by extending Medicare coverage of immunosuppressive drugs past 36 months for kidney transplant patients who do not obtain other health care coverage. This is a policy that has the support of everyone from patients to transplant surgeons. It also is something that the kidney community has coalesced behind for upwards of 15 years and has even received recent support from the Trump Administration.

In July, President Trump launched “Advancing American Kidney Health,” an initiative which aims to improve care and foster innovation to benefit kidney patients across the country.

H.R. 5534 aligns with the goals of the Administration. In fact, both the Centers for Medicare & Medicaid Services (CMS) Office of the Actuary and the US Health and Human Services (HHS) Office of the Assistant Secretary for Planning and Evaluation have published reports on the benefits of extending Medicare coverage of immunosuppressive drugs. The reports include financial savings for the Medicare program totaling approximately $300 million over 10 years.

CLICK HERE to read the op-ed.


Subcommittees
Health (116th Congress)
In the News